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Abstract
A key factor in dendritic cell (DC)-based tumor immunotherapy is the identification of an immunoadjuvant capable of
inducing DC maturation to enhance cellular immunity. The efficacy of a 50S ribosomal protein L7/L12 (rplL) from
Mycobacterium tuberculosis Rv0652, as an immunoadjuvant for DC-based tumor immunotherapy, and its capacity for
inducing DC maturation was investigated. In this study, we showed that Rv0652 is recognized by Toll-like receptor 4 (TLR4)
to induce DC maturation, and pro-inflammatory cytokine production (TNF-alpha, IL-1beta, and IL-6) that is partially
modulated by both MyD88 and TRIF signaling pathways. Rv0652-activated DCs could activate naı¨ve T cells, effectively
polarize CD4+ and CD8+ T cells to secrete IFN-gamma, and induce T cell-mediated-cytotoxicity. Immunization of mice with
Rv0652-stimulated ovalbumin (OVA)-pulsed DCs resulted in induction of a potent OVA-specific CD8+ T cell response, slowed
tumor growth, and promoted long-term survival in a murine OVA-expressing E.G7 thymoma model. These findings suggest
that Rv0652 enhances the polarization of T effector cells toward a Th1 phenotype through DC maturation, and that Rv0652
may be an effective adjuvant for enhancing the therapeutic response to DC-based tumor immunotherapy.
Citation: Lee SJ, Shin SJ, Lee MH, Lee M-G, Kang TH, et al. (2014) A Potential Protein Adjuvant Derived from Mycobacterium tuberculosis Rv0652 Enhances
Dendritic Cells-Based Tumor Immunotherapy. PLoS ONE 9(8): e104351. doi:10.1371/journal.pone.0104351
Editor: Jian-Xin Gao, Shanghai Jiao Tong University School of Medicine, China
Received January 1, 2014; Accepted July 13, 2014; Published August 7, 2014
Copyright:  2014 Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean Government (NRF-2012R1A2A1A03008433,
NRF-2012R1A1A4A01007325, and NRF-2011-0028573), a grant from the National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of
Korea (1120390). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: jungid@kku.ac.kr (IDJ); immun3023@kku.ac.kr (YMP)
. These authors contributed equally to this work.
Introduction
Dendritic cells (DCs) are the most important regulators of naı¨ve
cells during the generation of T cell-mediated immune responses,
and DCs are the most potent antigen-presenting cells (APCs) [1].
Because of their central role in modulating cellular immunity, DCs
are promising as potent adjuvants for the induction of tumor-
specific helper and cytotoxic T cells in tumor-bearing hosts [2,3].
Immunization with DCs loaded ex vivo with tumor-associated
antigens (Ags) is a promising approach for inducing effective
antitumor immunity [4]. This approach has been successfully
applied to vaccinations to activate cytotoxic T lymphocyte (CTL)
responses [5–8]. Early clinical trials have shown that tumor
vaccine therapies using DCs activated tumor Ags alone do not
generate an effective antitumor immune response, even though
this strategy has been successful in the treatment of tumors in
murine models [5,6,9–11]. Several mechanisms may account for
the limited effectiveness of DC vaccine induced immunity against
tumors. One possibility is that insufficient numbers of CTLs, the
effector cells that are considered optimal for causing tumor
regression, are activated in response to vaccination with tumor Ag
loaded DCs [12]. To overcome this limitation of DC-based
antitumor immunotherapeutic strategies, several factors related to
in vitro DC manipulation are important for inducing a powerful
immune response. Because DC maturation is critical for the
generation of effective immunity in therapeutic studies [13], it is
important to consider the regulation of DC maturation. Im-
munostimulatory adjuvants used to enhance DC maturation are
required to generate endogenous CTL responses and tumor
elimination.
The use of Toll-like receptor (TLR)-mediated DC activation
may be an effective cancer treatment strategy because TLR
activation usually induces Th1 responses [14,15]. When a ligand is
bound by a TLR, signaling occurs via two adaptor molecules in
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the cytoplasm: myeloid differentiation primary response protein 88
(MyD88) and Toll/IL-1R domain-containing adaptor inducing
IFNbeta (TRIF). TRIF is used for signaling by all TLRs except for
TLR3 [16]. Synthetic agonists of TLR3, TLR4, TLR5, TLR7,
TLR8, and TLR9 have been identified as suitable immunostim-
ulants [17–22], and simultaneous engagement of more than one
TLR have resulted in better immune stimulation in vitro [23].
Based on the efficacy of TLR agonists used thus far, the use of
TLR ligands as adjuvants in humans is likely to increase in the
future. Thus, DC activation by various microbes via TLR
signaling is the critical link between innate and adaptive immunity
and is crucial for generating protective immune responses.
Proteins that polarize the activated immune systems toward a
Th1 response are expressed by specific bacteria of the genus
Mycobacterium and related genera, and these adjuvants are
predicted to be crucial components of immunotherapeutic
strategies [24]. A significant amount of effort has been focused
on characterizing all mycobacterial proteins to identify antigenic
proteins that can be used as vaccine candidates for tuberculosis
therapy [24]. Mycobacterium tuberculosis ligands such as PE-
PGRS and LprA are known to interact with and activate APCs,
specifically DCs [25,26]. However, the mechanisms mediating the
interaction between these mycobacterial proteins and the host,
which contribute to the development of vaccine adjuvants for
diseases, have not been adequately clarified. It has been suggested
recently that M. tuberculosis heparin-binding hemagglutinin
(HBHA) is a potent immune adjuvant with potential applications
in antitumor immunotherapy [27]. Together, these reports
demonstrate the potential usefulness of mycobacterial proteins in
DC-based antitumor immunotherapy.
M. tuberculosis protein Rv0652, the 50S ribosomal protein (rp)
L7/L12 (rplL) [28], is a mixture of the L7 and L12 components of
heat-stable purified protein derivative proteins which are trigger a
strong delayed-type hypersensitivity reaction [29]. The rplL
protein is involved in translation factor binding, GTP-hydrolysis,
and translocation [30,31]; however, little is known regarding the
function of Rv0652 or the mechanism by which this protein
influences innate and adaptive immunity.
The biological activity and cellular immunity of M. tuberculosis
Rv0652 in DCs and their potential as adjuvants in DC-based
antitumor immunotherapy are described. Rv0652 is shown to be a
potent TLR4 agonist, inducing the MyD88 and TRIF signaling
pathways, and possibly enhancing DC activation and Th1
polarization. Notably, Rv0652 mediated a strong induction of
Ag-specific, CD8+ class I-restricted, CTL responses, and E.G7
tumor regression in vivo. These results highlight the potential use
of Rv0652 for DC-based antitumor immunotherapy.
Materials and Methods
Mice
Male 6 to 8-week-old C57BL/6 (H-2Kb and I-Ab) mice were
purchased from the Korean Institute of Chemistry Technology
(Daejeon, Korea). C57BL/6 OT-I and C57BL/6 OT-II T-cell
receptor transgenic mice, C57BL/6J TLR2 knockout mice
(TLR22/2; B6.129-Tlr2tm1Kir/J), C57BL/10 TLR4 knockout
mice (TLR42/2; C57BL/10ScNJ), MyD88 knockout mice, and
TRIF-deficient mice aged 6–8 weeks were purchased from Jackson
Laboratory (Bar Harbor, ME). Mice were housed in a specific
pathogen-free environment within an animal facility for at least 1
week before the experiment. All animal procedures were
performed in accordance with the protocols approved by the
Konkuk University Institutional Animal Care and Committee and
the recommendations for the proper use and care of laboratory
animals (IACUC number: KU13047).
Cell lines
EL4, a thymoma-derived cell line from the C57/BL/6 (H-2Kb
and I-Ab) mouse, and E.G7, an ovalbumin (OVA)-expressing EL4
variant, were purchased from the American Type Culture
Collection (Manassas, VA) and cultured in RPMI 1640 medium
supplemented with 10% heat-inactivated FBS, 100 U/ml penicil-
lin, 100 ug/ml streptomycin, and 10 mM L-glutamine (all
purchased from Invitrogen, Carlsbad, CA) at 37uC in 5% CO2.
Reagents and antibodies
Recombinant mouse granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF), interleukin (IL)-4, CCL19, and the FITC-
annexin V/propidium iodide kit were purchased from R&D
Systems (Minneapolis, MN). Dextran-FITC (40, 000 Da) was
purchased from Sigma-Aldrich (St. Louis, MO). Lipopolysaccha-
ride (LPS, from Escherichia coli O111: B4) was purchased from
Invivogen (San Diego, CA). H-2Kb-restricted OVA peptide
(OVA257–264) and H-2b-restricted OVA peptide (OVA323–339)
were synthesized by Peptron (Daejeon, Korea). The following
FITC- or PE-conjugated monoclonal Abs were purchased from
BD Biosciences (San Jose, CA): CD11c (HL3), CD80 (16-10A1),
CD86 (GL1), Iab beta-chain (AF-120.1), H-2Kb (AF6-88.5),
CCR7 (CD197), IL-10 (JESS-16E3), and IL-12p40/p70 (C15.6).
Alexa568 conjugated anti-mouse IgG antibodies were purchased
from Invitrogen (Eugene, OR). FITC-conjugated Mouse IgG Abs
and cytokine ELISA kits for murine IL-1beta, IL-2, IL-6, IL-10,
IL-12p70, TNF-alpha, and IFN-gamma were purchased from
eBiosciences (San Diego, CA).
Expression and purification of recombinant Rv0652
protein
Recombinant Rv0652 (rRv0652) protein was produced using
pET28a vector (Promega, Madison, WI) and an Escherichia coli
expression system, as recently described (26). Briefly, rplL
encoding Rv0652 was amplified by polymerase chain reaction
(PCR) using M. tuberculosis H37Rv genomic DNA (ATCC27294)
as template and the following primers: forward, 59-GGG CCC
GGA TCC ATG GCA AAG CTC TCC-39; and reverse 59-GGG
CCC GAA TTC CTT GAC GGT GAC GGT-39. The PCR
product was cut with BamHI and EcoRI and then inserted into
pET28a vector cut with the same restriction enzymes. The
recombinant plasmid was transformed into E. coli BL21 cells
carrying bacteriophage DE3 for protein overexpression.
DC generation and culture
DCs were isolated and cultured as recently described [32]. In
some experiments, DCs were labeled with bead-conjugated anti-
CD11c mAb and positively selected (.95%) according to the
manufacturer’s instructions (LS columns; Miltenyi Biotec, Auburn,
CA).
Therapeutic implanted tumor experiments
Mice were injected subcutaneously (s.c.) into the right lower
back with EL4 or E.G7 thymoma cells (26106 cells), followed by
tail vein injection of immature and Rv0652-treated DCs (16106
cells), some of which were pulsed with OVA (1 ug/ml) on days 1,
3, and 5 after tumor inoculation. Groups of tumor-bearing mice
were treated with PBS, iDCs (immature DCs), DCs-OVA (DCs
pulsed with OVA peptide), LPS-DCs-OVA (LPS-treated DCs
pulsed with OVA peptide), or Rv0652-DCs-OVA (Rv0652-
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treated DCs pulsed with OVA peptide). Tumor size was measured
every 2 days, and tumor mass was calculated as: V= (2A6B)/2,
where A is the length of the short axis and B is the length of the
long axis.
Confocal laser scanning microscopy
Cells were fixed with 4% paraformaldehyde (PFA), then stained
with anti-mouse Rv0652 and Alexa568 conjugated anti-mouse
IgG antibodies overnight at 4uC to detect Rv0652. Fluorescence
intensity was analyzed using a confocal laser scanning microscope
(Zeiss, Germany). Images were acquired using LSM510 Meta
software and processed using the LSM image examiner.
Antigen uptake and migration of DCs
Antigen uptake and in vitro and in vivo chemotaxis were
performed as previously described (26).
Mixed lymphocyte reaction
In brief, DCs were incubated with Rv0652 or LPS in the
presence or absence of OVA257–264 (0.5 ug/ml) or OVA323–339
(0.5 ug/ml) for 24 h. CFSE-labeled OT-I and OT-II T-cells were
seeded in triplicate wells at a density of 16105 cells per well,
together with DCs at a density of 16104 cells per well, in U-
bottomed 96-well microtiter culture plates (Nunc). Cells were
harvested after 96 h, stained with Cy5-labeled anti-CD8 and anti-
CD4 monoclonal Abs, and analyzed by flow cytometry (BD
Biosciences).
Ex vivo CTL assay and ELISA for IFN-gamma and IL-2
BALB/c mice were injected with PBS, untreated DCs (iDC),
DCs pulsed with OVA257–264 (DC-OVA), or Rv0652-treated DCs
pulsed with OVA257–264 (Rv0652-DC-OVA) on days 1 and 7.
Spleen cells (26106 per well) from injected mice (day 10) were
restimulated with 10 ug/ml OVA257–264 for 7 days in 6-well plates,
then co-cultured with EL4 [16106, 0.5 uM CFSE-stained
(CFSElow)] and E.G7 [16106, 10 uM CFSE-stained (CFSEhigh)]
cells. After 2 days, mixed cells were analyzed for cytotoxicity
against tumor cells by flow cytometry. After 1 day, the culture
supernatant was used for IFN-gamma and IL-2 ELISAs.
Statistical analysis
Statistical significance was assessed using the Student’s paired t-
test. Differences with a p-values of ,0.05 were considered
statistically significant. Datasets of survival curves were analyzed
using the Kaplan–Meyer log-rank test. Statistical analyses were
conducted using GraphPad Prism 4 software.
Results
Rv0652 enhances the expression of surface molecules
and induces maturation of functional DCs via TLR4
signaling
Various microbial antigens are recognized by receptors on DCs
including TLRs. Signaling by TLRs on DCs after antigen
recognition is required to induce an adequate host immune
response [14,15]. To identify which DC TLRs are involved in
recognition of Rv0652, we first tested TLR2 and TLR4. DCs from
WT, TLR22/2, or TLR42/2 mice were stimulated with Rv0652
(0.5 ug/ml), and Rv0652 was detected on the cell surface with
Alexa568-conjugated anti-Rv0652 monoclonal antibodies.
Rv0652 bound to the surfaces of WT and TLR22/2 DCs, but
not TLR42/2 DCs, (Fig. 1A-(i) and 1A-(ii)).
During maturation, DCs upregulate surface molecules and
acquire the ability to produce a broad variety of cytokines,
including IL-12 [1]. To determine whether Rv0652 can affect to
DC maturation, the surface molecules expressed on DCs after
stimulation by Rv0652 were measured. Upregulation of surface
molecules was dose-dependent in Rv0652-stimulated DCs
(Rv0652-DCs) (Fig. 1B). Cytokine production in Rv0652-DCs
was significantly increased, especially IL-12p70, a key cytokine for
the polarization of T cells toward the Th1 phenotype, while IL-10,
a cytokine with a critical role in Th2 polarization, was produced
by Rv0652-DCs at a similar level to that in untreated DCs
(Fig. 1C). This suggests that Rv0652 could be used as an adjuvant
for the induction of Th1 immune response when using DC
vaccines. Rv0652 stimulation also induced high levels of pro-
inflammatory cytokine production, such as TNF-alpha, IL-6, and
IL-1beta (Fig. 1D) and significantly decreased the capacity of
antigen uptake in DCs. The capacity for antigen uptake is
decreased during DC maturation that occurs after antigen
recognition and uptake, a phenomenon that is similar to what is
observed after LPS treatment of DCs (data not shown). These
results indicate that Rv0652 significantly enhanced both the
phenotypic and functional maturation of DCs.
To analyze the ability of Rv0652 to activate DCs via TLR4, the
expression of surface molecules and IL-1beta production were
compared in Rv0652-treated WT, TLR22/2, and TLR42/2
DCs. Surface molecule (Fig. 1E) and IL-1beta production (Fig. 1F)
were increased in WT and TLR22/2 DCs, but such effects were
strongly diminished in TLR42/2 DCs. These results indicated
that Rv0652 was a ligand for TLR4 on DCs, and that binding of
Rv0652 to TLR4 significantly increased the expression of proteins
that are markers for mature DCs and induced functional
maturation. The surface markers and signaling pathways induced
by TLR4 in DCs are similar to those identified when assessing the
role of TLR4 signaling in macrophages [33].
The effect of Rv0652 purity and endotoxin contamination
on cell viability
Soluble rRv0652 was carefully purified from in E. coli under
endotoxin-free experimental conditions. Using the LAL endotoxin
assay kit (GenScript USA, Inc, Piscataway, NJ, USA), we
confirmed that endotoxin contamination of rRv0652 did not
occur (,15 pg/ml) (Data not shown). As shown in Fig. 2A, the
purity of rRv0652 was analyzed using an immunoblot with anti-
histidine and an anti-Rv0652 Abs. The apparent molecular mass
of purified rRv0652 was approximately 22 kDa. Recombinant
Rv0652 is composed of 130 amino acids, as shown in Supple-
mentary Figure1. Proteinase K- or heat-treated rRv0652 lost the
ability to stimulate IL-1beta production in DCs. The activity of
rRv0652 was resistant to polymyxin B treatment, indicating that
LPS contamination was not responsible for the observed effects
(Fig. 2B).
Next, we examined the effect of rRv0652 on the viability of DCs
by performing FACS analysis of PI/Annexin V stained cells. As
shown in Fig. 2C, rRv0652-DCs at concentrations up to 1 ug/ml
had no effect on cell viability, indicating that the purity of rRv0652
was sufficient for use in DC maturation induction. The activation
of TLR4 signaling in DCs by rRv0652 recognition, and the
induced maturation of DCs, did not affect cell viability when less
than 1 ug/ml rRv0652 was used.
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MyD88- and TRIF-signaling pathways contribute to pro-
inflammatory cytokine production in Rv0652-DCs
The production of pro-inflammatory cytokines, especially IL-
1beta, by Rv0652-DCs was induced through the TLR4 signaling
pathway (Fig. 1F). TLR4 signaling typically proceeds via MyD88-
and TRIF-dependent pathways [34]. To investigate the involve-
ment of the MyD88- and TRIF-signaling pathways on cytokine
production in Rv0652-DCs, pro-inflammatory cytokine produc-
tion in Rv0652-DCs from WT, MyD882/2 and TRIF-deficient
mice were compared. The rRv0652-induced production of IL-
1beta, IL-6, and TNF-alpha was partially inhibited in the absence
of MyD88 and TRIF (Fig. 3). Taken together, our results suggest
that TLR4, MyD88, and TRIF are involved in optimal rRv0652-
induced pro-inflammatory cytokine responses in DCs.
rRv0652 induces DC migration
CCR7, a receptor important for the migration of activated DCs
to a secondary lymphoid organ after antigen recognition and
Figure 1. Rv0652 binds to TLR4 but not TLR2, and induces phenotypic and functional maturation of DCs. (A) Fluorescence microscopic
observation of Rv0652 binding on DCs. (i) DCs derived from WT, TLR22/2, and TLR42/2mice were treated with Rv0652 (0.5 ug/ml) for 1 h and stained
with Alexa568-conjugated anti-Rv0652 mAb and FITC-conjugated CD11c+ Ab. The percentage of labeled cells was analyzed by flow cytometry. The
percentage of positive cells is shown in each panel. Bar graphs show the mean and standard error of the mean (SEM) for the percentage of Rv0652-
Alexa568 labeled CD11c+ cells observed in 3 independent experiments. ***P,0.001 compared to Rv0652-treated WT DCs. (ii) DCs derived from WT,
TLR22/2, and TLR42/2 mice were treated with Rv0652 (0.5 ug/ml) for 1 h, fixed, and stained with DAPI and Alexa568-conjugated anti-Rv0652 mAb.
One representative experiment out of 3 with similar results is shown. (B) Flow cytometry was used to analyze the expression of surface molecules on
CD11c+ cells. The mean fluorescence intensity (MFI) and the percentage of positive cells are shown in each panel (i). Bar graphs show the percentage
of surface molecule-expressing CD11c+ cells, representing 5 independent experiments. *P,0.05, **P,0.01, and ***P,0.001 compared to medium
control (ii). (C, D) ELISA was performed to test IL-12p70, IL-10, TNF-alpha, IL-6, and IL-1beta production in Rv0652- and LPS-treated DCs. The presented
data are the mean and SEM of 3 experiments. *P,0.05, **P,0.01, and ***P,0.001 compared to untreated DCs. (E–F) DCs derived from WT, TLR22/2,
and TLR42/2 mice were treated with Rv0652 (1 ug/ml) or LPS (200 ng/ml) for 24 h. (E) Flow cytometry was used to analyze the expression of surface
molecules on CD11c+ cells. The percentage of positive cells is shown in each panel (i). Bar graphs show the percentage of surface molecule-
expressing CD11c+ cells, representing 4 independent experiments. *P,0.05, **P,0.01, and ***P,0.001 compared with WT cultures (ii). (F) The
supernatants were harvested and an ELISA was performed to test IL-1beta production. Data are means and SEM of 3 experiments. ***P,0.001,
compared to WT cultures.
doi:10.1371/journal.pone.0104351.g001
Figure 2. Purity and endotoxin contamination of the rRv0652 protein and its effect on cell viability. (A) Recombinant Rv0652 protein
was purified with NTA resin, subjected to SDS-PAGE, and analyzed by using Coomassie blue (CB) staining (left panel) and immunoblot assay using
anti-histidine and anti-Rv0652 antibodies (right panel). (B) DCs were stimulated with vehicle, Rv0652 (1 ug/mL), or LPS (200 ng/mL), and treated with/
without polymyxin B (10 ug/mL), proteinase K (5 ug/ml), or heat (100uC for 30 min). Culture supernatants were harvested after 24 h, and IL-1beta
levels were assessed by an ELISA. Data are the mean and SEM of 3 experiments. ***P,0.001. (C) DCs were treated with the indicated concentrations
of Rv0652 or LPS (200 ng/mL) for 24 h, stained with Annexin V and PI, and analyzed by flow cytometry. Results are representative of 4 separate
experiments with similar results.
doi:10.1371/journal.pone.0104351.g002
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uptake in the peripheral tissue, was expressed in DCs during
maturation [35,36]. To investigate whether rRv0652 affects DC
migration, CCR7 expression was measured on DCs. CCR7
expression was increased in Rv0652-DCs, to levels similar to those
of DCs treated with LPS at 1 ug/ml (Fig. 4A). The migration of
DCs in response to CCL19 was examined in vitro by using a
transwell migration assay. Increased migration of DCs was
observed (Fig. 4B), consistent with the upregulation of CCR7
expression. To further confirm the migratory capacity of Rv0652-
DCs, we investigated the number of CFSE-positive DCs in the
draining LNs (dLNs) in vivo. The number of CFSE-positive DCs
in the dLNs was significantly higher in the Rv0652-treated groups
compared to those lacking Rv0652 treatment (Fig. 4C). Overall,
the migration of DCs from the periphery to secondary lymphoid
organs is crucial for their interaction with other immune cells,
especially T cells, and the induction of a cellular immune response
for cancer immunotherapy. These results demonstrate that
rRv0652 promotes DC migration in vitro and in vivo, and they
suggest antigen-specific T cell responses might be induced by
Rv0652-DCs.
Rv0652-DCs enhance CD8+ and CD4+ T cell proliferation
A major role of mature DCs is antigen presentation to T cells,
and subsequent T cell activation. To characterize the effect of
Rv0652 on DC and T-cell interactions, we performed a syngenic
mixed lymphocyte reaction assay by using OT-I T cell receptor
(TCR) transgenic CD8+ T cells and OT-II TCR transgenic CD4+
T cells [37]. Co-culture of CD4+ or CD8+ T cells (CFSE-labeled
and OVA-specific) with Rv0652-DCs pulsed with OVA257–264
(Fig. 5A) or OVA323–339 (Fig. 5B) induced a significantly higher
rate of proliferation than the co-culture of CD4+ or CD8+ T cells
(CFSE-labeled and OVA-specific) with DCs that were pulsed with
OVA257–264 or OVA323–339, but not stimulated with rRv0652.
Syngeneic CD4+ and CD8+ T cells primed with Rv0652-DCs
produced significantly (P#0.05–0.01) higher levels of IFN-gamma
production than those primed with iDCs (Fig. 5C). These results
suggest that rRv0652 induces DC maturation and production of
IL-12p70 from DCs. Rv0652-DCs could be used in cancer
immunotherapy to indirectly potentiate CD4+ T cell differentia-
tion towards a Th1 phenotype, leading to the production of IFN-
gamma and direct activation of OVA-specific CD8+ T cells.
Rv0652 enhances the efficacy of DC-based antitumor
immunotherapy
Antigen-specific T cell activation by Rv0652-DCs was observed
(Fig. 5); therefore, a mouse tumor model implanted with EL4 or
OVA-expressing E.G7 cells was used to determine the potential
usefulness of an Rv0652-DC antitumor vaccine. DCs pulsed with
OVA257–264 (OVA-DCs) and injected intravenously resulted in a
significantly slower growth of E.G7 tumors than intravenous
injection of PBS or iDCs (Fig. 6A), but did not affect EL4 tumor
growth (Fig. 6B). Interestingly, E.G7 tumors in mice that received
Rv0652-DCs pulsed with OVA257–264 (Rv0652-OVA-DCs) and
mice that received LPS-DCs pulsed with OVA257–264 (LPS-OVA-
DCs) as positive control were significantly smaller than E.G7
tumors in mice that received OVA-DCs (Fig. 6A). Notably, only
20% of mice injected with OVA-DCs survived beyond 60 days
following E.G7 tumor implantation, while over 60% of mice
injected with Rv0652-OVA-DCs survived longer than 60 days. All
mice in the PBS and iDC-injected groups had a median survival of
34 days with no long-term survivors (Fig. 6C).
Rv0652 increases CTL activity in tumor-bearing mice
Rv0652-DCs had an antitumor effect through T cell activation
(Fig. 5), inhibition of tumor growth, and extended survival (Fig. 6).
To determine whether T cells activated with Rv0652-DCs actually
exerted tumor-killing effects, we examined ex vivo CTL activity
and cytokine production, including that of IFN-gamma and IL-2.
Figure 3. Rv0652-induced cytokine production is partially
mediated by MyD88- and TRIF-pathways. DCs derived from WT,
MyD882/2, and TRIF-deficient mice were treated with Rv0652 (1 ug/ml)
or LPS (200 ng/ml) for 24 h. The supernatants were harvested and ELISA
was performed to test TNF-alpha, IL-6, and IL-1beta production. Data
are means and SEM of 3 experiments. **P,0.01 and ***P,0.001,
compared to WT cultures.
doi:10.1371/journal.pone.0104351.g003
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CTLs from mice injected with OVA-DCs lysed E.G7-OVA target
cells more efficiently than CTLs from mice injected with PBS or
iDCs (Fig. 7A). CTLs from mice injected with Rv0652-OVA-DCs
in E.G7 as well as LPS-OVA-DCs (the positive control) were able
to lyse target cells at a significantly greater rate than CTLs from
mice injected with OVA-DCs (Fig. 7A). IFN-gamma and IL-
2 secretion from splenocytes (Fig. 7B-a) and tumor-infiltrating
CD8+ T cells (Fig. 7B-b) from mice injected with Rv0652-OVA-
DCs and then re-stimulated with OVA257–264, was higher than the
IFN-gamma and IL-2 secretion from splenocytes and tumor-
infiltrating CD8+ T cells from mice injected with OVA-DCs. This
indicates that the antitumor effect of Rv0652-OVA-DCs is closely
related to the production of IFN-gamma and IL-2, as well as CTL
activity (Fig. 7B). These data suggest that rRv0652 acts as a Th1-
polarizing adjuvant. We examined whether administration of
Rv0652-OVA-DCs enhanced the number of CD8+CD69+ T cells,
the phenotype of activated CD8+ T cells. The number of activated
CD8+ T cells from mice injected with OVA-DCs was higher than
that of mice injected with either PBS or iDCs. More importantly,
the number of activated CD8+ T cells from mice injected with
Rv0652-OVA-DCs was greater than that of the mice injected with
OVA-DCs (Fig. 7C). These results indicate that Rv0652-OVA-
DCs can induce an antitumor immune response by increasing the
antitumor activity of CTLs.
Discussion
The immune system can recognize many tumor Ags; however,
the ability of tumors to escape a host immune system suggests that
the immune mechanism is insufficient for effectively killing certain
tumors. In an attempt to strengthen antitumor immunity, we
focused on a DC-based therapeutic strategy, using M. tuberculosis
Rv0652.
DCs are the most potent APCs and versatile regulators of T
lymphocyte responses. Immature DCs capture Ags, process them,
and present them on the cell surface, in association with MHC
class I or II molecules, to prime CD8+ CTLs or CD4+ T helper 1
cells, respectively [1]. Immunization with DCs loaded ex vivo with
tumor Ag, is a promising strategy for inducing efficient antitumor
immunity [4] that has been successfully used to vaccinate mice and
to activate CTL responses in preclinical trials [5–8].
We showed that rRv0652 could induce antigen specific
antitumor effects by triggering DC maturation. Rv0652 improved
the efficacy of DC-based antitumor immunotherapy in mice by
acting as a potent adjuvant. Evidence for these novel character-
istics of rRv0652 include: 1) increased expression of surface
molecules (CD80/CD86); 2) involvement of the MyD88- and
TRIF-pathways in the production of pro-inflammatory cytokines
induced by Rv0652 in DCs; 3) DC activation was not due to
endotoxin contamination and occurred via TLR4 but not TLR2
signaling; 4) there is an increased migratory capacity in Rv0652-
DCs; 5) the effect of Rv0652-DCs on the expansion of IFN-
Figure 4. Rv0652 enhances the migration of DCs in vitro and in vivo. (A) DCs were treated with the indicated concentrations of Rv0652 or LPS
(200 ng/ml) for 24 h. The percentage of CCR7+CD11c+ DCs was analyzed by flow cytometry. The number in each panel indicates the percentage of
positive cells (i). Bar graphs show the percentage of CCR7-expressing CD11c+ cells, representing 4 independent experiments. *P,0.05 and ***P,
0.001 compared to the media control (ii). (B) DCs were treated with Rv0652 or LPS for 24 h and then subjected to an in vitro transwell chemotaxis
assay using media alone or media containing CCL19 (300 ng/ml). Recorded data are the mean and SEM of 4 experiments. ***P,0.001, compared to
untreated DCs. (C) CFSE-labeled Rv0652 (1 ug/ml)- or LPS (200 ng/ml)-treated DCs were injected subcutaneously into the hind leg footpad of mice,
the cells were recovered from popliteal LNs 72 h later and then analyzed. Data are the mean and SEM of 4 experiments. **P,0.05 compared to
untreated DCs.
doi:10.1371/journal.pone.0104351.g004
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gamma-producing CD4+ and CD8+ T cells; and 6) significantly
elevated Ag-specific CTL antitumor activity against an E.G7-
OVA expressing thymoma.
Co-stimulatory signals, such as CD40, CD80, and CD86 as well
as cytokines including IL12p70 from Ag-specific and activated
DCs are required for the induction of proper host immunity
mediated by helper CD4+ and cytotoxic CD8+ T cells. We found
that Rv0652-DCs significantly increased their surface molecules
and the production of IL-12p70, which is essential for Th1
polarization [38]. In addition, the interaction of T cells with
Rv0652-DCs led to a higher rate of primary syngenic T cell
proliferation than untreated DCs. The activation of T cells is a
crucial event for an effective immune response against a tumor,
and Rv0652-DCs induced IFN-gamma production in CD4+ and
CD8+ T-cells. The production of IFN-gamma is an important
feature of Th1 immune responses, and this result suggests that
Rv0652 may promote a Th1 immune response through the
activation and maturation of DCs. Furthermore, Rv0652 protein
enhanced CCR7 expression, which is crucial for DC migration
from the periphery into the paracortex of secondary lymphoid
organs [35,36]. Rv0652-DCs migrate towards CCL19 in vitro and
to draining LNs in vivo. Therefore, Rv0652 affects DC function in
multiple ways, and Rv0652 may be an effective adjuvant for DC-
based antitumor immunotherapy.
TLRs are expressed by numerous immune cells and play key
roles in innate and adaptive immune responses [39]. Among
various TLRs, TLR4 agonism potentially results in more efficient
DC maturation and enhances Ag presentation to T cells [40].
Adjuvant studies for cancer vaccine treatments have recently
focused on TLR4 agonists because these receptors mediate signals
from the innate immune system via MyD88- and TRIF-dependent
pathways, and these appear to be important immunopotentiators
Figure 5. Rv0652-treated DCs induce proliferation of CD4+ and CD8+ T cells and a Th1 response. Transgenic OVA-specific CD8+ T cells (A-
i) and OVA-specific CD4+ T cells (B-i) were isolated and stained using CFSE. These cells were then co-cultured for 96 h with untreated DCs, DCs pulsed
with OVA257–264, Rv0652 (1 ug/ml)-treated DCs pulsed with OVA257–264, or LPS (200 ng/ml)-treated DCs pulsed with OVA257–264. T-cell proliferation
was assessed using flow cytometry and the percentage of proliferating cells is shown in each panel. Bar graphs show the percentage of OVA-specific
CD8+ T cells (A-ii) and OVA-specific CD4+ T cells (B-ii) from 3 independent experiments. ***P,0.001 compared to T cells/OVA pulsed-DCs. (C) IFN-
gamma production was measured in each culture supernatant from Fig. 5A and 5B after 24 h of culture by performing an ELISA. Data are the mean
and SEM of 3 experiments. ***P,0.001 compared to the value from T cell/OVA peptide-pulsed DCs.
doi:10.1371/journal.pone.0104351.g005
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[41]. Although LPS, the most studied and well-characterized
TLR4 agonist, is highly effective as an adjuvant in both
experimental and preclinical settings [42], it is not suitable for
clinical use due to its toxicity in humans. Thus, novel TLR4
agonists are needed for use as adjuvants in tumor and infectious
disease vaccine production, especially when using DC-based
vaccination strategies.
Several purified M. tuberculosis ligands, such as LprA [25], and
PE-PGRS [26] have now been identified as TLR2 agonists that
induce APC activation [43]. Our group recently showed that M.
tuberculosis HBHA is a novel TLR4 agonist for antitumor
vaccinations [27]. We also made the novel observation that M.
tuberculosis Rv0652, similar to HBHA, directly binds TLR4 and
activates TLR4 signaling, leading to the expression of co-
stimulatory and MHC antigen presentation molecules, as well as
the production of IL-1beta by DCs. Kim et al [33] have observed
similar results in macrophages stimulated with Rv0652. Most
information regarding the role of MyD88 and TRIF in mediating
cytokine production by TLR4 has come from studies employing
LPS and DnaK as TLR4 agonists. Our results suggested that
intracellular adapters such as MyD88 and TRIF are partially
involved in mediating pro-inflammatory cytokine production in
Rv0652-DCs. Although MyD88- and TRIF-mediated signaling is
essential for an optimal Rv0652-induced cytokine response by
DCs, there is a possibility that other signaling pathways are
involved in pro-inflammatory cytokine production, since
MyD882/2 and TRIF2/2 DCs still produce small amounts of
pro-inflammatory cytokines. Further study is necessary to fully
understand this process.
Systemic intravenous (Fig. 6) and subcutaneous (Supplementary
Fig. 2) injection of Rv0652-treated, OVA peptide-pulsed DCs
induced a marked suppression of tumor growth. Using the
Systemic intravenous injection model, we observed that the
antitumor activity of Rv0652 originates from a marked increase
in IFN-gamma production by the T cells in draining LNs that are
primed by DCs stimulated with Rv0652, an increase in the
number of functional Ag-specific CTLs, and increased tumor
infiltration of CD8+CD69+ T cells. Taken together, this increase in
antitumor efficacy was attributed to the enhancement of Th1
polarization by Rv0652-DCsthat activate the CTLs that are able
to lyse tumor cells. Our data indicate that M. tuberculosis Rv0652
can be used in DC-based antitumor immunotherapy.
Figure 6. Rv0652-treated DCs pulsed with OVA257–264 protects mice against E.G7 tumor challenge. C57BL/6 mice were challenged s.c
with 36105 E.G7 or EL4 tumor cells into the right flank area. For administration of DCs (16106 cells/mice), mice were injected intravenously with PBS,
iDC, DCs-OVA (DCs pulsed with OVA257–264), Rv0652-DCs-OVA (Rv0652-treated DCs pulsed with OVA257–264), or LPS-DCs-OVA (LPS-treated DCs pulsed
with OVA257–264) on days 1, 3 and 5 after the tumor challenge. Following the tumor challenge with E.G7 (A) and EL4 (B), tumor growth was monitored
by measuring the diameter of the tumor every 2 days. **P,0.01, each group, n = 10. (C) Survival of mice with an E.G7 tumor challenge after injection
of OVA peptide-pulsed and Rv0652-treated DCs, n = 10 mice/group. P value calculated by Kaplan-Meyer log-rank test between two groups of mice
injected with DCs-OVA and Rv0652-DCs-OVA, respectively.
doi:10.1371/journal.pone.0104351.g006
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Supporting Information
Figure S1 Amino acid sequence of Rv0652 (www.tbdb.
org).
(TIF)
Figure S2 Rv0652-treated DCs pulsed with OVA257–264
protects mice against E.G7 tumor challenge. C57BL/6
mice were challenged s.c with 36105 E.G7 tumor cells into the
right flank area. For administration of DCs (16106 cells/mice),
mice were injected subcutaneously with PBS, iDC, DCs pulsed
with OVA257–264, or Rv0652-treated DCs pulsed with OVA257–264
on days 1, 3 and 5 after the tumor challenge. (A) Following tumor
challenge with E.G7 tumor growth was monitored by measuring
the diameter every 2 days. *P,0.05, each group, n = 10. (B)
Survival of mice with E.G7 tumor challenge after injection of
OVA peptide-pulsed and Rv0652-treated DCs, n= 10 mice/
group. P value calculated by Kaplan-Meyer log-rank test between
two groups of mice injected with iDC and Rv0652-DC-OVA,
respectively.
(TIF)
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